Contact LinkedIn Twitter Home About Technology Pipeline Patients News & Media Investors Join Our Crew Overview News & Events Company Info Financial Info Stock Data SEC Filings Analyst Coverage Governance Company Information COMPANY INFO Overview Management Team Presentations Contacts FAQ Company Profile Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases, and exploring their potential to provide deep, durable, and potentially curative responses. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate the pathogenic B cells that express disease-causing autoantibodies while sparing normal B cells, leaving the healthy immune system intact. Our technology, in combination with our proprietary Cabaletta Approach for selective B cell Ablation (CABA™) platform, has applicability across more than two dozen B cell-mediated autoimmune diseases. Using our CABA™ platform, we have discovered and developed five disclosed product candidates, including our lead clinical-stage therapy in development to treat patients with mucosal pemphigus vulgaris. We hold multiple agreements with the University of Pennsylvania and other academic institutions to develop CAAR T cell therapies. Our goal is to leverage our team’s expertise in autoimmunity and engineered T cell therapy and our network of collaborators to rapidly discover and develop our portfolio of CAAR T product candidates. Latest Presentation Corporate Presentation View This Presentation Industry Classifications Sector: Healthcare Industry: Biotechnology NAICS: Pharmaceutical Preparation Manufacturing (325412) SIC: Pharmaceutical Preparations (2834) Contact Information Investor Relations Anup Marda Chief Financial Officer investors@cabalettabio.com Stern Investor Relations, Inc. Sarah McCabe sarah.mccabe@sternir.com Company Contact Cabaletta Bio, Inc. 2929 Arch Street Suite 600 Philadelphia, PA 19104 Email Alerts Contacts RSS News Feed About Technology Pipeline Patients News & Media Investors Join Our Crew 2929 Arch Street Suite 600 Philadelphia, PA 19104 © 2021 Cabaletta Bio, Inc. All Rights Reserved. Privacy Policy Disclaimer Terms of Use Sitemap

Contact LinkedIn Twitter Home About Technology Pipeline Patients News & Media Investors Join Our Crew Press Releases Presentations Events Cabaletta Bio to Participate in Upcoming Investor Conferences in November About Technology Pipeline Patients News & Media Investors Join Our Crew 2929 Arch Street Suite 600 Philadelphia, PA 19104 © 2021 Cabaletta Bio, Inc. All Rights Reserved. Privacy Policy Disclaimer Terms of Use Sitemap

Contact LinkedIn Twitter Home About Technology Pipeline Patients News & Media Investors Join Our Crew Overview DesCAARTes™ Phase 1 Trial Expanded Access Policy Patients About Technology Pipeline Patients News & Media Investors Join Our Crew 2929 Arch Street Suite 600 Philadelphia, PA 19104 © 2021 Cabaletta Bio, Inc. All Rights Reserved. Privacy Policy Disclaimer Terms of Use Sitemap